Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial
Read Article
Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. Traditionally, a bimodal distribution by age has been
Read Article
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
A meta-analysis and systematic review of six
Read Article
Giant cell arteritis (GCA) has a different phenotype when diagnosed late in life compared with earlier onset, a large Italian cohort study indicated.
Features of what might be called "senior GCA" include increased rates of cranial symptoms, a markedly higher risk for aortic aneurysm
Read Article
Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease:
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK
Links:
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally. This adult disorder has a mean age at diagnosis of nearly 50 years and affects both sexes equally,
Read Article
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
Read Article
Links:
Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg
Links:
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised. A EULAR task force has established recommendations for screening and prophylaxis against OI.
Read Article
A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).
Previous studies have shown an increased risk of VTE in DM patients, usually within 2 years of onset. Moreover, the FDA has recently
Read Article
A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
Epidemiologic data and outcomes were gleaned from analysis of commercial
Read Article
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in
Read Article
Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.
Read Article
Senescence pathways are involved in giant cell arteritis (GCA), an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development.
Temporal artery biopsy samples from GCA patients showed
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271
Links:
BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.
BRIDGE-PMR was a 21 week randomised
Read Article
British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
Read Article
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic
Read Article
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV. A
Read Article
A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
This was a retrospective single-centre analysis of IIM patients
Read Article
